Susceptibility and protection against human autoimmune diseases, including type I diabetes, multiple sclerosis, and Goodpasture disease, is associated with particular human leukocyte antigen (HLA) alleles. However, the mechanisms underpinning such HLA-mediated effects on self-tolerance remain unclear. Here we investigate the molecular mechanism of Goodpasture disease, an HLA-linked autoimmune renal disorder characterized by an immunodominant CD4 + T-cell selfepitope derived from the α3 chain of type IV collagen (α3 135-145 ) + T-cell repertoire. Accordingly, we provide a mechanistic basis for the dominantly protective effect of HLA in autoimmune disease, whereby HLA polymorphism shapes the relative abundance of self-epitope specific T reg cells that leads to protection or causation of autoimmunity.
+ T-cell repertoire. Accordingly, we provide a mechanistic basis for the dominantly protective effect of HLA in autoimmune disease, whereby HLA polymorphism shapes the relative abundance of self-epitope specific T reg cells that leads to protection or causation of autoimmunity.
Using HLA-DR15-α 3 135-145 tetramers, we found that α 3 135-145 -specific CD4 + T cells in peripheral blood of HLA-DR15 + patients with Goodpasture disease are ~ 100-fold more frequent than in healthy HLA-DR15 + donors. T reg cells can be important in limiting this disease 5 , but in seven out of eight patients the HLA-DR15-α 3 135-145 -specific T cells were mainly Foxp3 − T conv ( Fig. 1a and Extended Data Table 1 
Fcgr2b
+/+ mice, make pro-inflammatory responses after ex vivo stimulation with α 3 [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] or α 3(IV)NC1, consistent with the lower risk of anti-glomerular basement membrane (anti-GBM) disease in humans 2 . Furthermore, in DR15
+ DR1 + Fcgr2b +/+ mice, α 3 135-145 immunization did not induce pro-inflammatory autoreactivity to α 3 135-145 , or α 3(IV)NC1 (Fig. 1c) . DR15
+ , DR1 + and DR15 + DR1 + mice had similar overall HLA expression, similar overall proportions of Foxp3 + cells and no T-cell antigen receptor (TCR) beta variable (TRBV) skewing of their entire CD4
+ cell repertoire (Extended Data Fig. 2a ). The dominant negative effect of HLA-DR1 was specific to the area of α 3(IV)NC1 containing the immunodominant α 3 136-146 sequence (Extended Data Fig. 2b ). Thus, HLA-DR15-restricted pro-inflammatory autoreactivity to α 3 135-145 is abrogated by co-expression of the HLA-DR1 allele.
Next, we characterized the self-peptide repertoires of the HLA-DR15 and HLA-DR1 allomorphs [6] [7] [8] [9] from naive DR15 + and DR1 + mice [10] [11] [12] . A total of 5,965 HLA-DR15 and 7,015 HLA-DR1 bound peptides were identified, from which consensus peptide binding motifs were derived using IceLogo 11 ( Fig. 1d) . Coincident with the canonical HLA-DR peptide anchor positions P1, P4, P6/7 and P9, the peptide positions p1, p4, p6 and p9 showed strong but distinct amino-acid preferences for HLA-DR15 and HLA-DR1. Findings were similar using human DR15/DR51, and DR1-expressing cell lines (Extended Data Fig. 3a, b and Supplementary Data).
We hypothesized that the polymorphisms between HLA-DR15 and HLA-DR1 affect the presentation of α 3 [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] . Here, 9 out of the 13 polymorphic differences reside within the antigen binding cleft (Fig. 2a) . We solved the structures of HLA-DR15-α 3 135-145 and HLA-DR1-α 3 [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] (Extended Data Table 2 and Extended Data Fig. 3c-f) . The overall structures of HLA-DR15 and HLA-DR1 were closely matched (0.6 Å root mean square deviation over 360 Cα atoms; Fig. 2a) . In HLA-DR15-α 3 135-145 the peptide binding register of α 3 135-145 was Letter reSeArCH GWISLWKGFSF (pHLA positions p1-p9 underlined), and thus the canonical HLA-DR peptide binding pockets were occupied by the peptide sidechains of p1-Ile, p4-Trp, p7-Phe and p9-Phe (Fig. 2b) . This peptide binding register was in agreement with the peptide elution data (Fig. 1d) . Each of the anchor residues (p1-Ile, p4-Trp and p7-Phe) made direct interactions with one or more polymorphic residues of HLA-DR15. Namely, p1-Ile was buried inside the P1 pocket, where it contacted the polymorphic Val86 (Fig. 2b, e) , and p4-Trp lay flat in the P4 pocket and interacted with the polymorphic residues Arg13, Phe26, Asp28 and Ala71. In the adjacent P6/7 pocket, p7-Phe contacted the polymorphic residues Asp28, Tyr30, Phe47 and Ile67. Notably, the P4 and P6/7 pockets were not structurally separated, which appeared to be reflected in the enrichment of bulky and aromatic residues in p4 and p7 of HLA-DR15-eluted peptides (Fig. 1d) .
The peptide binding register of HLA-DR1-α 3 135-145 , GWISLWKGFSF, was distinct from HLA-DR15-α 3 [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] : that is, it was shifted by one position towards the peptide amino (N) terminus (Fig. 2c) . Interestingly, the binding of MBP [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] to HLA-DR51 is characterized by a three-amino-acid register shift compared with its binding to HLA-DR15 (ref. 13 ). Overlay of the peptides bound by HLA-DR15 and HLA-DR1 showed a difference in the peptide backbone conformations largely attributable to a flipped peptide bond between p5 and p6, resulting in differences of p6, p7 and p8 Cα positions of 2.2 Å, 2.5 Å and 1.5 Å, respectively (Fig. 2d) . The peptide in HLA-DR1-α 3 135-145 was anchored via the residues p1, p4, p6 and p9. The register shift was accompanied with a positional switch of the peptide anchor residue residing in the P6/P7 pocket (p6-Lys in HLA-DR1 and p7-Phe in HLA-DR15). The observed peptide binding register shift was in agreement with the peptide elution data of HLA-DR1 (Fig. 1d) , as it placed the preferred anchor residues p1-Trp and p4-Leu in the P1 and P4 pockets, respectively (Fig. 2c, f) . Compared with P1 of HLA-DR15, the P1 pocket of HLA-DR1 had a 190 Å 3 larger volume due to the polymorphic residue Gly86 (Val86 in HLA-DR15). This allowed P1 of HLA-DR1 to accommodate p1-Trp, while P1 of HLA-DR15 would be unable to accommodate a Trp residue. The P4 and P6/7 pockets of HLA-DR1 were structurally segregated by the polymorphic residue Arg71 (Ala71 in HLA-DR15). This restricted the available space in the P4 pocket compared with HLA-DR15. Compared with HLA-DR15, P6/7 of HLA-DR1 provided additional space underneath the peptide because of the presence of Cys30 and Phe13 (Tyr30 and Arg13 in HLA-DR15). Therefore, differences in shape and aperture of the P6/7 pocket allowed p6-Lys to reach underneath the peptide and act as a peptide anchor residue in HLA-DR1, forming a salt bridge with Glu28 ( Fig. 2f) , whereas HLA-DR15 p7-Phe bound laterally with respect to the peptide. Thus, the dominant negative effect of HLA-DR1 in anti-GBM disease is accompanied by register-shifted binding of α 3 135-145 to HLA-DR1 and consequently a distinctly different peptide-HLA landscape.
We next addressed whether this altered pHLA landscape caused differences in the responding T-cell repertoire (Fig. 2g) . Namely, HLA-DR1-α 3 135-145 -restricted T cells from DR1 + mice were more likely to bear TCR alpha variable 14 (TRAV14) than HLA-DR15-α 3 135-145 + T cells from DR15 + mice. In contrast, HLA-DR15-α 3 135-145 -restricted TCRs exhibited TRBV bias, with TRBV19 present in 17 out of 100 T cells, but absent in the HLA-DR1-α 3 135-145 T-cell repertoire. Notably, experiments in DR15 + DR1 + mice showing DR1-α 3 135-145 TRAV14 usage and DR15-α 3 135-145 TRBV19 usage demonstrated that, even in the presence of both HLA-DR15 and HLA-DR1, α 3 135-145 -specific TCR usage is determined by the individual HLA molecule in a similar manner to mice transgenic for either HLA-DR15 or HLA-DR1 (Fig. 2g) . We also found significant differences in the overall TCR distribution in the TCR alpha joining (TRAJ) region usage in the α 3 135-145 TCR repertoire between DR15 + and DR1 + mice (Extended Data Fig. 4a ). These findings demonstrate that the altered pHLA landscapes result in differences in the responding T-cell repertoire.
Next, we ascertained whether differences in α 3 135-145 -specific TCR usage between HLA-DR15 and HLA-DR1 were accompanied by functional phenotypic differences. We found that CD4 + T cells specific for this epitope from naive DR15 + mice were largely CD4 + transgenic mice. Enriched and depleted amino acids are shown above and below the horizontal bar, respectively; scale of letter proportional to frequency difference. Values are mean ± s.e.m.; * P < 0.05; * * P < 0.01; * * * P < 0.001 by Mann-Whitney U-test (a, b) or Kruskal-Wallis test (c).
in response to α 3 135-145 peptide ( Fig. 3b and Extended Data Fig. 5a ). Furthermore, T reg cells from DR1 + mice were substantially more potent in suppressing the development of α 3 136-146 -induced responses in CD4 +
CD25
− T cells from DR15 + DR1 + mice when they included α 3 135-145 -specific T reg cells (Extended Data Fig. 5b ). Therefore, the dominant protection of HLA-DR1 from the HLA-DR15 conferred risk of anti-GBM disease is through the induction of α 3 135-145 -specific T reg cells.
We assessed the capacity of T reg cells in vivo to prevent autoimmunity to α 3 135-145 using HLA transgenic mice in experimental Goodpasture disease. Consistent with the in vitro findings (Fig. 3b) , HLA-DR15 + mice developed reactivity towards α 3 135-145 , with or without T reg depletion; whereas, even with T reg depletion, DR1 + mice did not develop pro-inflammatory reactivity to α 3 135-145 after immunization with this peptide. However, in DR15
+ mice, T reg depletion unmasked significant autoreactivity, with evidence of T H 1 and T H 17 responses (Fig. 3c ) 4, 14 . Furthermore, T reg depletion in DR15 + T cells in HLA-DR transgenic mice (pooled samples, n = 3 mice each group), and phenotyping for Vα2 (TRAV14) and Vβ6 (TRBV19). Tet + cells, tetramer-positive cells. Frequencies of TCRs between DR15 and DR1 were compared by Fisher's exact test, ***P < 0.001. For flow cytometry, n = 4 individual mice per group, *P < 0.05; ***P < 0.001 by unpaired two-tailed t-test. 
+ Fcgr2b −/− n = 4 each group and DR15 + DR1 + Fcgr2b −/− n = 8 (T reg intact), 9 (T reg depleted)). Scale bars, 30 μ m. b, In the blood of healthy HLA-typed humans, α 3 135-145 -specific CD4
+ T conv cells predominate in the setting of DR15 and T reg cells with DR1. c, In humans, only CD4 + T cells from healthy DR15 homozygotes (n = 6) exhibit pro-inflammatory autoreactivity to α 3 135-145 when T reg cells are present, while T reg cells in DR1 homozygotes (n = 5) and DR15/DR1 heterozygotes (n = 5) proliferate and secrete tolerogenic cytokines. Values are mean ± s.e.m.; * P < 0.05; * * P < 0.01; * * * P < 0.001 by Mann-Whitney U-test (a-c, top panels) and Kruskal-Wallis test (c, bottom). (Fig. 4a) . In T regdepleted mice, CD4
+

Foxp3
+ T reg cells were reduced at days 7 and 14 during the development of autoimmunity, but restored by day 21 (Extended Data Fig. 6a) , and mice immunized with a control peptide (OVA 323-339 ) did not develop disease (Extended Data Fig. 6b ). DR15
+ Fcgr2b
−/− mice developed anti-GBM disease (Fig. 4a and Extended Data Fig. 6c, d) , with no significant increase in most parameters after early T reg depletion. DR1
+
Fcgr2b
−/− mice were protected from disease after α 3 135-145 immunization, and T reg depletion did not provoke renal disease. DR15
−/− mice did not develop disease, demonstrating the dominant protection of HLA-DR1 in vivo in this system. Critically, after T reg depletion, α 3 135-145 -immunized DR15
mice developed severe glomerulonephritis of similar severity to DR15 + Fcgr2b −/− mice, phenotypically similar to human anti-GBM disease, with the classic and diagnostic serum anti-α 3(IV)NC1 autoantibodies and immunoglobulin-G (IgG) deposition on the GBM as well as glomerular infiltration of effector cells and elevated messenger RNA (mRNA) for intrarenal pro-inflammatory cytokines ( Fig. 4a and Extended Data Fig. 6c, d) . Therefore, endogenous HLA-DR1-associated α 3 135-145 -specific T reg cells abrogate the DR15-mediated increased risk of developing Goodpasture disease and dominantly protect from this autoimmune disease.
Next we examined α 3 135-145 -specific CD4 + T cells from fully HLAtyped healthy blood donors who were either HLA-DR15 homozygotes, HLA-DR1 homozygotes or DR15/DR1 heterozygotes (Extended Data lo cells were removed before culture, pro-inflammatory responses emerged in T cells from DR15/DR1 heterozygotes, but not HLA-DR1 homozygote healthy donors; whereas in the context of DR1, T reg cells exhibited α 3 135-145 -specific proliferation and cytokine production (Fig. 4c) . The α 3 135-145 -specific CD4 + T-cell repertoire also showed evidence of skewing, in the TRBV gene usage (Extended Data  Fig. 7a ). We also examined the α 3 135-145 -specific TCR repertoire in the peripheral blood of two patients with acute Goodpasture disease and found that conserved HLA-DR15-α 3 135-145 -specific CD4 + TCR sequences were present in both the TRAV and TRBV regions (Extended Data Fig. 7b ) of the patients, particularly in patient GP1 who exhibited identical sequences in 6 out of 12 TRAV and 4 out of 16 TRBV analyses. The repeat sequences in HLA-DR15-α 3 135-145 tetramer + CD4 + T cells in patients with Goodpasture disease provide further evidence that the α 3 135-145 epitope plays a pivotal role in this disease.
Other autoimmune diseases with HLA associations, including type I diabetes and multiple sclerosis, have reported dominantly protective or modulatory HLA alleles [15] [16] [17] . Currently, the mechanisms underpinning such dominant protective HLA effects are unclear, although several theories, including epitope capture, T-cell deletion and T reg dominance, have been proposed. Here, we have used Goodpasture disease as a model human autoimmune disease to mechanistically determine how an HLA allele can exert its dominant protective effect. Our structural and T-cell repertoire data show that neither epitope capture nor T-cell deletion are the mechanisms at play here. Instead, the dominant protective effect of HLA-DR1 is associated with α 3 135-145 -specific T reg cells. In Goodpasture disease, a register shift in the binding of the immunodominant autoreactive peptide to HLA-DR1 compared with HLA-DR15 leads to fundamental differences between their CD4 + α 3 135-145 -specific TCR repertoire and phenotype. Our studies therefore provide a mechanistic basis for understanding HLA-mediated susceptibility and protection in autoimmune disease.
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Human participants. Patients who were included in the study all had Goodpasture disease and fulfilled the following key diagnostic criteria: (1) serum anti-α 3(IV) NC1 IgG by enzyme-linked immunosorbent assay (ELISA), (2) linear IgG staining of the GBM and (3) necrotizing and crescentic glomerulonephritis. HLA-DR15 typing of patients was done by monoclonal antibody staining (BIH0596, One Lambda) and flow cytometry. Blood from HLA-typed healthy humans was collected via the Australian Bone Marrow Donor Registry. HLA-DR15, HLA-DR1 and HLA-DR15/DR1 donors were molecularly typed and were excluded if they expressed DQB1* 03:02, which is potentially weakly associated with susceptibility to anti-GBM disease 2 . Studies were approved by the Australian Bone Marrow Donor Registry and Monash Health Research Ethics Committees, and informed consent was obtained from each individual. Humanized HLA transgenic mice. Mouse MHCII deficient, DR15 transgenic mice and mouse MHCII deficient, DR1 transgenic mice were derived from existing HLA transgenic colonies and intercrossed so that they were on the same background as previously described 4 . The background was as follows: 50% C57BL/10, 43.8% C57BL/6, 6.2% DBA/2; or with an Fcgr2b −/− background: 72% C57BL/6, 25% C57BL/10 and 3% DBA/2. To generate mice transgenic for both HLA-DR15 and HLA-DR1, mice transgenic for either HLA-DR15 or HLA-DR1 were intercrossed. Fcγ RIIb intact HLA transgenic mice and cells were used for all experiments, except those in experimental Goodpasture disease, where Fcgr2b . To promote correct pairing, the carboxy (C) termini of the HLA-DR15 and HLA-DR1 α -and β -chain encoded enterokinase cleavable Fos and Jun leucine zippers, respectively. The β -chains also encoded a C-terminal BirA ligase recognition sequence for biotinylation and a poly-histidine tag for purification. HLA-DR15-α 3 135-145 and HLA-DR1-α 3 135-145 were purified from baculovirus-infected High Five insect cell supernatants through successive steps of immobilized metal ion affinity (Ni Sepharose 6 Fast-Flow, GE Healthcare), size exclusion (S200 Superdex 16/600, GE Healthcare) and anion exchange (HiTrap Q HP, GE Healthcare) chromatography. For crystallization, the leucine zipper and associated tags were removed by enterokinase digestion (Genscript, New Jersey, USA) further purified by anion exchange chromatography, buffer exchanged into 10 mM Tris, pH 8.0, 150 mM NaCl and concentrated to 7 mg ml −1
. Tetramer generation and sample analysis. Purified HLA-DR15-α 3 135-145 and HLA-DR1-α 3 135-145 proteins were buffer exchanged into 10 mM Tris pH 8.0, biotinylated using BirA ligase and tetramers assembled by addition of Streptavidin-PE (BD Biosciences) as previously described 19 . In mice, 10 7 splenocytes or cells from kidneys were digested with 5 mg ml −1 collagenase D (Roche Diagnostics, Indianapolis, Indiana, USA) and 100 mg ml −1 DNase I (Roche Diagnostics) in HBBS (Sigma-Aldrich) for 30 min at 37 °C, then filtered, erythrocytes lysed and the CD45 + leukocyte population isolated by MACS using mouse CD45 microbeads (Miltenyi Biotec); they were then surface stained with Pacific Blue-labelled antimouse CD4 (BD), antigen-presenting cell (APC)-Cy7-labelled anti-mouse CD8 (BioLegend) and 10 nM PE-labelled tetramer. Cells were then incubated with a Live/Dead fixable Near IR Dead Cell Stain (Thermo Scientific), permeabilized using a Foxp3 Fix/Perm Buffer Set (BioLegend) and stained with Alexa Fluor 647-labelled anti-mouse Foxp3 antibody (FJK16 s). To determine Vα 2 and Vβ 6 usage, cells were stained with PerCP/Cy5.5 anti-mouse Vα 2 (B20.1, Biolegend) and antigen-presenting cell labelled anti-mouse Vβ 6 (RR4-7, Biolegend). For each mouse a minimum of 100 cells were analysed. The tetramer + gate was set on the basis of the CD8 + population. In humans, 3 × 10 7 white blood cells were surface stained with BV510-labelled anti-human CD3 (BioLegend), Pacific Blue-labelled anti-human CD4 (BioLegend), PE-Cy7-labelled anti-human CD127 (BioLegend), FITC-labelled anti-human CD25 (BioLegend) and 10 nM PE-labelled tetramer. Then, cells were incubated with a Live/Dead fixable Near IR Dead Cell Stain (Life Technologies), permeabilized using a Foxp3 Fix/Perm Buffer Set (BioLegend) and stained with Alexa Fluor 647-labelled anti-human Foxp3 antibody (150D). The tetramer + gate was set on the basis of the CD3 + CD4 − population. As validation controls, we found that HLA-DR1-α 3 135-145 tetramer + cells did not bind to HLA-DR1-CLIP tetramers (data not shown). α3(IV)NC1 peptides and proteins. The human α 3 135-145 peptide (GWISLWKGFSF), the mouse α 3 136-146 peptide (DWVSLWKGFSF) and control OVA 323-339 peptide (ISQAVHAAHAEINEAGR) were synthesized at > 95% purity, confirmed by high-performance liquid chromatography (Mimotopes). Recombinant murine α 3(IV)NC1 was generated using a baculovirus system 21 and recombinant human α 3(IV)NC1 expressed in HEK 293 cells ) or whole recombinant human α 3(IV)NC1 (10 μ g ml
) in supplemented RPMI media (10% male AB serum, 2 mM l-glutamine, 50 μ M 2-ME, 100 U ml −1 penicillin and 0.1 mg ml ) in supplemented RPMI media (10% FCS, 2 mM l-glutamine, 50 μ M 2-ME, 100 U ml −1 penicillin and 0.1 mg ml −1 streptomycin). Cells were cultured for 18 h at 37 °C, 5% CO 2 and the data expressed as numbers of IFN-γ or IL-17A spots per well. To determine the immunogenic portions of α 3(IV)NC1, mice were immunized subcutaneously with peptide pools (containing α 3 amino acids 1-92, 81-164, or 153-233; 10 μ g per peptide per mouse), the individual peptide or in some experiments mα 3 136-146 at 10 μ g per mouse in Freund's complete adjuvant (SigmaAldrich). Draining lymph node cells were harvested 10 days after immunization and stimulated in vitro (5 × 10 5 cells per well) with no antigen, peptide (10 μ g ml
) or whole α 3(IV)NC1 (10 μ g ml −1 ) in supplemented RPMI media (10% FCS, 2 mM l-glutamine, 50 μ M 2-ME, 100 U ml −1 penicillin and 0.1 mg ml streptomycin). For Letter reSeArCH nodes (pooled from five mice in each group) or frozen pellets of human B lymphoblastoid cell lines (triplicate samples of 10 9 cells) were cryogenically milled and solubilized as previously described 12, 27 , cleared by ultracentrifugation and MHC peptide complexes purified using LB3.1 coupled to protein A (GE Healthcare). Bound HLA complexes were eluted from each column by acidification with 10% acetic acid. The eluted mixture of peptides and HLA heavy chains was fractionated by reversed-phase high-performance liquid chromatography as previously described 10 . Liquid chromatography-tandem mass spectrometry acquisition and analysis. Peptide-containing fractions were analysed by nano-liquid chromatographytandem mass spectrometry (nano-LC-MS/MS) using a ThermoFisher Q-Exactive Plus mass spectrometer (ThermoFisher Scientific, Bremen, Germany) operated as described previously 10 . LC-MS/MS data were searched against mouse or human proteomes (Uniprot/Swissprot v2016_11) using ProteinPilot software (SCIEX) and resulting peptide identities subjected to strict bioinformatic criteria including the use of a decoy database to calculate the false discovery rate 28 . A 5% false discovery rate cut-off was applied, and the filtered data set was further analysed manually to exclude redundant peptides and known contaminants as previously described 29 . The mass spectrometry data have been deposited in the ProteomeXchange Consortium via the PRIDE 30 partner repository with the data set identifier PXD005935. Motif analysis. Minimal core sequences found within nested sets of peptides with either N-or C-terminal extensions were extracted and aligned using MEME (http://meme.nbcr.net/meme/), where motif width was set to 9-15 and motif distribution to 'one per sequence' 31 . Graphical representation of the motif was generated using IceLogo . The structures were solved by molecular replacement in PHASER 35 and refined by iterative rounds of model building using COOT 36 and restrained refinement using Phenix 37 (see Extended Data Table 2 for data collection and refinement statistics). Statistics. No statistical methods were used to predetermine sample size. For normally distributed data, an unpaired two-tailed t-test (when comparing two groups). For non-normally distributed data, non-parametric tests (Mann-Whitney U-test for two groups or a Kruskal-Wallis test with Dunn's multiple comparison) were used. Statistical analyses, except for TCR usage, was by GraphPad Prism (GraphPad Software). For each TCR type/region (TRAV, TRBV, TRAJ, TRBJ), we compared the TCR distribution (frequencies of different TCRs) between DR15 and DR1 using Fisher's exact test. This was applied both to mice and to human samples. The P values associated with those TCR distributions are indicated above the pie-charts. To correct for multiple testing for individual TCRs, we used Holm's method. * P < 0.05, * * P < 0.01, * * * P < 0.001. Data availability. The data that support the findings of this study are available from the corresponding authors upon request. Self-peptide repertoires have been deposited in the Proteomics Identifications Database archive with the accession code PXD005935. Structural information has been deposited in the Protein Data Bank under accession numbers 5V4M and 5V4N. lymph node cells from DR15 + DR1 + mice in supplemented RPMI media (10% FCS, 2 mM l-glutamine, 50 μ M 2-ME, 100 U ml −1 penicillin and 0.1 mg ml −1 streptomycin) containing 100 μ g ml −1 of mouse α 3 [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] . To determine proliferation, the CD4 +
CD25
− T effector cells were labelled with CTV before culture. Cells were cultured in triplicate for 8 days in 96-well plates. Induction and assessment of experimental autoimmune anti-GBM
4
. HLA transgenic mice, on an Fcgr2b −/− background, were immunized with 100 μ g of α 3 135-145 or mα 3 136-146 subcutaneously on days 0, 7 and 14, first in Freund's complete, and then in Freund's incomplete, adjuvant. Mice were killed on day 42. Albuminuria was assessed in urine collected during the last 24 h by ELISA (Bethyl Laboratories) and expressed as milligrams per micromole of urine creatinine. Blood urea nitrogen and urine creatinine were measured using an autoanalyser at Monash Health. Glomerular necrosis and crescent formation were assessed on periodic acid-Schiff (PAS)-stained sections; fibrin deposition using anti-murine fibrinogen antibody (R-4025) and DAB (Sigma); CD4 + T cells, macrophages and neutrophils were detected using anti-CD4 (GK1.5), anti-CD68 (FA/11) and anti-Gr-1 (RB6-8C5) antibodies. The investigators were not blinded to allocation during experiments and outcome assessment, except in histological and immunohistochemical assessment of kidney sections. To deplete regulatory T cells, mice were injected intraperitoneally with 1 mg of an anti-CD25 monoclonal antibody (clone PC61) or rat IgG (control) 2 days before induction of disease. In these experiments, mice were randomly assigned to receive control or anti-CD25 antibodies. Single-cell multiplexed RT-PCR. Individual DR15-α 3 135-145 -specific CD4 + T cells were sorted into wells of a 96-well plate. Multiplex single-cell reverse transcription and PCR amplification of TCR CDR3α and CDR3β regions were performed using a panel of TRBV-and TRAV-specific oligonucleotides, as described 24, 25 . Briefly, mRNA was reverse transcribed in 2.5 μ l using a Superscript III VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA) (containing 1× Vilo reaction mix, 1× superscript RT, 0.1% Triton X-100), and incubated at 25 °C for 10 min, 42 °C for 120 min and 85 °C for 5 min. The entire volume was then used in a 25 μ l first-round PCR reaction with 1.5 U Taq DNA polymerase, 1× PCR buffer, 1.5 mM MgCl 2 , 0.25 mM dNTPs and a mix of 25 mouse TRAV or 40 human TRAV external sense primers and a TRAC external antisense primer, along with 19 mouse TRBV or 28 human TRBV external sense primers and a TRBC external antisense primer (each at 5 pmol μ l −1 ), using standard PCR conditions. For the second-round nested PCR, a 2.5 μ l aliquot of the first-round PCR product was used in separate TRBV-and TRAV-specific PCRs, using the same reaction mix described above; however, a set of 25 mouse TRAV or 40 human TRAV internal sense primers and a TRAC internal antisense primer, or a set of 19 mouse TRBV or 28 human TRBV internal sense primers and a TRBV internal antisense primer, were used. Second-round PCR products were visualized on a gel and positive reactions were purified with ExoSAP-IT reagent. Purified products were used as template in sequencing reactions with internal TRAC or TRBC antisense primers, as described. TCR gene segments were assigned using the IMGT (International ImMunoGeneTics) database 26 . In mouse experiments, three mice were pooled per HLA and the number of sequences obtained were as follows. For TRAV: DR15, n = 81; DR1 n = 84; for TRBV: DR15, n = 100; DR1 n = 87; for TRAJ: DR15, n = 81; DR1 n = 84; and for TCR beta joining (TRBJ): DR15, n = 100; DR1 n = 87. RT-PCR for tT reg genes. Red-blood-cell-lysed splenocytes from DR1 + and DRB15 + DR1 + mice were sorted on the basis of surface expression of CD4 and CD25 and being either DR1-α 3 135 HLA-DR1-α 3 135-145 tetramer + T reg cells. A minimum of 1,000 cells were sorted. Immediately after sorting, the RNA was isolated and complementary DNA (cDNA) generated using a Cells to Ct Kit (Ambion) followed by a preamplification reaction using Taqman Pre Amp Master Mix (Applied Biosystems), which preamplified the following cDNAs: Il2ra, Foxp3, Ctla4, Tnfrsf18, Il7r, Sell, Pdcd1, Entpd1, Cd44, Tgfb3, Itgae, Ccr6, Lag3, Lgals1, Ikzf2, Tnfrsf25, Nrp1, Il10. The preamplified cDNA was used for RT-PCR reactions in duplicate using Taqman probes for the aforementioned genes. Each gene was expressed relative to 18S, logarithmically transformed and presented as a heat map. Purification of MHC-bound peptides. The Epstein-Barr-virus-transformed human B lymphoblastoid cell lines IHW09013 (SCHU, DR15-DR51-DQ6) and IHW09004 (JESTHOM, DR1-DQ5) were maintained in RPMI (Invitrogen) supplemented with 10% FCS, 50 IU ml −1 penicillin and 50 μ g ml −1 streptomycin. Confirmatory tissue typing of these cells was performed by the Victorian Transplantation and Immunogenetics Service. The B-cell hybridoma LB3.1 (anti-DR) was grown in RPMI-1640 with 5% FCS at 37 °C and secreted antibody purified using protein A sepharose (BioRad). HLA-DR-presented peptides were isolated from naive DR15
+
Fcgr2b
+/+ or DR1
+
Fcgr2b
+/+ mice. Spleens and lymph
